Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1112

Sort by

Sort Order Select

Journal Articles

Sickle marrow: double, double toil and trouble

Mark C. Walters

Blood (2020) 135 (23): 2017–2018.

https://doi.org/10.1182/blood.2020005114

Published: 2020

Journal Articles

Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways

Denis F. Noubouossie, Michael W. Henderson, Micah Mooberry, Anton Ilich, Patrick Ellsworth, Mark Piegore, Sarah C. Skinner, Rafal Pawlinski, Ian Welsby, Thomas Renné, Maureane Hoffman, Dougald M. Monroe, Nigel S. Key

Blood (2020) 135 (10): 755–765.

https://doi.org/10.1182/blood.2019001643

Published: 2020

Includes: Supplemental data

Journal Articles

Genetic Association Studies of Red Blood Cell Transfusion Related Alloimmunization: A Systematic Review and Meta-Analysis

Jorn Gerritsma, MD, Ilja Oomen, BSc, Sanne Meinderts, PhD, C. Ellen van der Schoot, MD PhD, Bart J. Biemond, MD PhD, Johanna G van der Bom, MD PhD, Karin Fijnvandraat, MD PhD

Blood (2019) 134 (Supplement_1): 2459.

https://doi.org/10.1182/blood-2019-128199

Published: 2019

Journal Articles

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Ka-Won Kang, Hyemi Moon, Byung-Hyun Lee, MD, Min Ji Jeon, Eun Sang Yu, MD, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Seok Jin Kim, MD PhD, Chul Won Choi, Byung Soo Kim, Juneyoung Lee, Yong Park

Blood (2019) 134 (Supplement_1): 2227.

https://doi.org/10.1182/blood-2019-125269

Published: 2019

Journal Articles

An Ongoing Global, Longitudinal, Observational Study of Patients with Pyruvate Kinase Deficiency: The PEAK Registry

Rachael F. Grace, MD, Paola Bianchi, BSc, PhD, Bertil Glader, MD PhD, Andreas Glenthøj, MD PhD, Bryan Jones, PhD, Hitoshi Kanno, MD PhD, Kevin H. M. Kuo, MDMSc,FRCPC, D. Mark Layton, MB ChB, Eduard J. van Beers, MD PhD, Joan-Lluis Vives Corrons, MD PhD, Tu Xu, MS, PhD

Blood (2019) 134 (Supplement_1): 2223.

https://doi.org/10.1182/blood-2019-123059

Published: 2019

Journal Articles

Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium

Julie Kanter, MD, Mary Dooley, MS, Logan P Sirline, MPH, Martina Mueller, PhD, Shannon Phillips, PhD RN, Alyssa M Schlenz, PhD, Cathy Melvin, PhD MPH, Robert J. Adams, MD MS

Blood (2019) 134 (Supplement_1): 2270.

https://doi.org/10.1182/blood-2019-129951

Published: 2019

Journal Articles

Acute Chest Syndrome in Children with Sickle Cell Disease in Italy: Results of a National Survey from the Italian Association of Pediatric Hematology Oncology (AIEOP)

Vania Munaretto, Raffaella Colombatti, MD PhD, Serena Ilaria Tripodi, Corti Paola, MD, Simone Cesaro, Francesco Arcioni, C Piccolo, Tommaso Mina, MD, Marco Zecca, Daniela Cuzzubbo, Maddalena Casale, MD PhD, Giovanni Palazzi, Lucia Notarangelo, Nicoletta Masera, MD, Giovanna Russo, Laura Sainati, MD

Blood (2019) 134 (Supplement_1): 2301.

https://doi.org/10.1182/blood-2019-128215

Published: 2019

Journal Articles

Low-Dose Epo after Tgfβ Blockade Triggers Robust Erythropoiesis and Increased RBC Production

Silvana Di Giandomenico, PhD, Ghaith Abu Zeinah, MD, Pouneh Kermani, PhD, Mia Yabut, BS, Thomas Stephens, BS, Nassima Messali, PhD, Joseph Scandura, MD PhD

Blood (2019) 134 (Supplement_1): 2217.

https://doi.org/10.1182/blood-2019-129044

Published: 2019

Journal Articles

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

John Porter, Maria Domenica Cappellini, MD, Thomas Coates, MD, Olivier Hermine, Vip Viprakasit, MD DPhil, Ersi Voskaridou, Hong Keng Liew, Silverio Perrotta, Abderrahim Khelif, Antonis Kattamis, Abderrahmane Laadem, Jeevan K. Shetty, Wen-Ling Kuo, Dimana Miteva, Tatiana Zinger, Peter G. Linde, Daniel Sinsimer, Ali Taher

Blood (2019) 134 (Supplement_1): 2245.

https://doi.org/10.1182/blood-2019-122561

Published: 2019

Journal Articles

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

Drorit Grizim Merkel, MD, Abraham Avigdor, MD, Arnon Nagler, MD MSc, Ohad Benjamini, MD, Yaron Davidovitz, MD, Orly Goitein, MD

Blood (2019) 134 (Supplement_1): 5432.

https://doi.org/10.1182/blood-2019-125279

Published: 2019

Journal Articles

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

Kristen M Corrao, MD, Alexandra M. Harrington, MDMT(ASCP), Steven H. Kroft, MD, Laura C. Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Lyndsey Runaas, MD, Ehab L. Atallah, MD, Sameem Abedin, MD

Blood (2019) 134 (Supplement_1): 5430.

https://doi.org/10.1182/blood-2019-130511

Published: 2019

Journal Articles

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Jennifer O'Sullivan, MD, Jason A Taylor, MD PhD, Aaron T. Gerds, MD MS, Sarah A Buckley, MD, Claire N Harrison, Professor, Stephen T. Oh, MD, Kieran Howard, Helene Marie-Pierre Dreau, PhD, Angela Hamblin, MD PhD, Adam J. Mead, MD PhD

Blood (2019) 134 (Supplement_1): 4214.

https://doi.org/10.1182/blood-2019-129254

Published: 2019

Journal Articles

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2019) 134 (Supplement_1): 4248.

https://doi.org/10.1182/blood-2019-127435

Published: 2019

Journal Articles

Role of Disease Modifying Treatment in the Risk of Alloimmunization in Transfused Patients with Myelodysplastic Syndromes: A Population-Based Study

Hanne Rozema, MSc, Robby Kibbelaar, Dr., Nic Veeger, Dr., Mels Hoogendoorn, Dr., Eric van Roon, Prof. Dr.

Blood (2019) 134 (Supplement_1): 4253.

https://doi.org/10.1182/blood-2019-123357

Published: 2019

Journal Articles

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

Raajit K. Rampal, MD PhD, Srdan Verstovsek, MD PhD, Sean M. Devlin, PhD, Amber C. King, PharmD, BCOP, Eytan M. Stein, MD, Naveen Pemmaraju, MD, Michael J. Mauro, MD, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Kelsey Alvarez, RN, Nicole Ard, Tawni Goodman, Bria Taylor, Prithviraj Bose, MD

Blood (2019) 134 (Supplement_1): 4163.

https://doi.org/10.1182/blood-2019-127661

Published: 2019

Journal Articles

Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)

Guadalupe Belen Antelo, MD, Giacomo Coltro, MD, Abhishek A Mangaonkar, MBBS, Terra Lasho, PhD, Christy Finke, BS, Ryan M. Carr, MD PhD, Naseema Gangat, MBBS, Moritz Binder, MDMPH, Aref Al-Kali, MD, Michelle A Elliott, MD, Matthew T Howard, MD, Rebecca L. King, MD, William J Hogan, MB, BCh, Mark Litzow, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Martin Fernandez-Zapico, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 4182.

https://doi.org/10.1182/blood-2019-126199

Published: 2019

Journal Articles

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Patrick T. Ebbert, BS, Frederico Xavier, MD MS, Craig D. Seaman, MD MS, Margaret V. Ragni, MD MPH

Blood (2019) 134 (Supplement_1): 2416.

https://doi.org/10.1182/blood-2019-123198

Published: 2019

Journal Articles

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Montserrat Arnan Sangerman, Helena Pomares, MD PhD, Esther Alonso, MD, Javier Grau, MD PhD, Mercedes Galiano, Maite Encuentra, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 3013.

https://doi.org/10.1182/blood-2019-127486

Published: 2019

Journal Articles

Characterization of Response and Transfusion Independence in Patients with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial

Mark J. Levis, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Arnaud Lesegretain, Jeanne Mendell, PhD MPH, Derek E. Mires, PharmD, Yufen Zhang, PhD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2599.

https://doi.org/10.1182/blood-2019-124491

Published: 2019

Journal Articles

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Daisuke Araki, MD, Ma Evette Barranta, Fariba Chinian, MS, Julie Erb-Alvarez, MPH, Thomas Winkler, MD, Neelam Giri, MD, Andre Larochelle, MD PhD

Blood (2019) 134 (Supplement_1): 3753.

https://doi.org/10.1182/blood-2019-123151

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Sickle marrow: double, double toil and trouble

Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways

Genetic Association Studies of Red Blood Cell Transfusion Related Alloimmunization: A Systematic Review and Meta-Analysis

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

An Ongoing Global, Longitudinal, Observational Study of Patients with Pyruvate Kinase Deficiency: The PEAK Registry

Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium

Acute Chest Syndrome in Children with Sickle Cell Disease in Italy: Results of a National Survey from the Italian Association of Pediatric Hematology Oncology (AIEOP)

Low-Dose Epo after Tgfβ Blockade Triggers Robust Erythropoiesis and Increased RBC Production

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Role of Disease Modifying Treatment in the Risk of Alloimmunization in Transfused Patients with Myelodysplastic Syndromes: A Population-Based Study

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Characterization of Response and Transfusion Independence in Patients with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only